Search

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.

Key updates

ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022 Company plans to discuss findings from sepofarsen Illuminate trial w

Key updates

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).

LEIDEN, the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, the Netherlands, Sept. 14, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that PQ-010-002 is open for enrollment.

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology